Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial.

Area of Science:

• Neuroscience
• Immunology
• Psychiatry

Background:

• Interleukin-6 (IL-6) is implicated in depression pathogenesis.
• Randomized clinical trials on IL-6 inhibition for depression are limited.

Purpose of the Study:

• To assess treatment-sensitive outcomes and effect size of IL-6 inhibition in difficult-to-treat depression.
• To identify patient selection methods for IL-6 targeted therapies.

Main Methods:

• A 4-week, double-blind, placebo-controlled trial of tocilizumab in adults with moderate-to-severe depression and inflammation.
• Participants had poor antidepressant response and elevated hs-CRP levels.
• Primary outcome: depression somatic symptoms at 14 days post-infusion.

Main Results:

• Tocilizumab showed a pattern of improvement in somatic symptoms, depression severity, fatigue, anxiety, and quality of life over 28 days.
• Remission and response rates favored tocilizumab.
• Baseline hs-CRP levels predicted depression improvement, suggesting utility as a biomarker.

Conclusions:

• IL-6 inhibition with tocilizumab demonstrates potential for treating difficult-to-treat depression.
• Somatic symptoms, fatigue, and quality of life are promising treatment-sensitive outcomes.
• A large-scale efficacy trial is recommended to confirm these findings.